Ophthotech rebrands as Iveric as focus turns to retinal gene therapies

Ophthotech Corp. (NASDAQ:OPHT) changed its name and ticker to Iveric bio Inc. (NASDAQ:ISEE) as part of its shift to focus on gene therapies to treat orphan inherited retinal diseases.

Last week, the company exercised its option to obtain an exclusive, global license from the University of Pennsylvania and the University of Florida Research Foundation to adeno-associated virus (AAV) gene therapy candidates to treat Best vitelliform macular dystrophy and other bestrophinopathies. Iveric expects to start a Phase I/II trial in 1H21...